Carlos Alvarez-Guzman

Carlos Alvarez-Guzman

Auto-generated profile, based on publicly available information

Carlos Alvarez-Guzman

Tecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
ABAndres Bustamante-Arias
Andres Bustamante-Arias
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
JAJ. Carlos Alvarez-Guzman
J. Carlos Alvarez-Guzman
SGSara Gonzalez-Godinez
Sara Gonzalez-Godinez
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia

5 July 2022 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
CACarlos Alvarez-Guzman
Carlos Alvarez-Guzman
JVJorge E. Valdez-Garcia
Jorge E. Valdez-Garcia
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
CNCarlos F. Navas-Villar
Carlos F. Navas-Villar
MPMiguel Pedroza-Seres
Miguel Pedroza-Seres

13 August 2022 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
JAJimena Alamillo-Velazquez
Jimena Alamillo-Velazquez
GMGustavo Ortiz Morales
Gustavo Ortiz Morales
LGLucas A. Garza-Garza
Lucas A. Garza-Garza
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia

11 July 2022 in Journal of Ophthalmic Inflammation and Infection
Verified
Journal Article
Open access
PDF file
CACarlos Alvarez-Guzman
Carlos Alvarez-Guzman
CHCurt Hartleben-Matkin
Curt Hartleben-Matkin
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
JVJorge E. Valdez-Garcia
Jorge E. Valdez-Garcia
Background/purpose: Identify the prevalence and risk factors for secondary glaucoma among Mexican-mestizo patients with Vogt-Koyanagi-Harada Disease (VKH). Methods: Retrospective cohort study analyzing the demographic, clinical, and epidemiological variables. Risk estimates were calculated using a Cox proportional hazards regression model. Results: One hundred eyes of 50 patients, 44 (88%) women and 6 men (12%) with a median age of 35.5 years (IQR 29–46) and a median follow-up time of 72 months (IQR 13.7–126.7) were analyzed. The prevalence of glaucoma was 20%, with angle-closure accounting for 70% of all cases. Significant clinical risk factors for glaucoma development were a chronic recurrent stage at presentation (RR 2.88, 95% CI 1.11–12.63, p = 0.037), ≥ 2 episodes of recurrent anterior uveitis (RR 8.52, 95% CI 2.02–35.92, p < 0.001), angle-closure disease (ACD, RR 7.08, 95% CI 2.44–20.48, p < 0.001), iris bombé (RR 5.0, 95% CI 2.10–11.90, p < 0.001), and peripapillary atrophy (RR 3.56, 95% CI 1.43–8.85, p < 0.001). Exposure to > 24 months of oral (RR 9.33, 95% CI 2.21–39.28, p < 0.001) or > 12 months of topical corticosteroids (RR 3.88, 95% CI 1.31–11.46, p = 0.007) were associated with an increased likelihood for secondary glaucoma development. Conclusion: Glaucoma is a frequent complication of VKH, often attributed to mixed pathogenic mechanisms. Chronic disease at presentation, recurrent inflammation, angle-closure mechanisms, iris bombé, and peripapillary atrophy represent clinically significant risk factors for developing secondary glaucoma. Prompt and aggressive steroid-spearing immunosuppressive therapy for adequate inflammation control may lower the risk of glaucoma in VKH.

8 November 2024 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
ECEduardo Camacho-Martinez
Eduardo Camacho-Martinez
CACarlos Alvarez-Guzman
Carlos Alvarez-Guzman
APAngelina Espino Barros Palau
Angelina Espino Barros Palau
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
To compare the treatment outcome and visual prognosis of Vogt-Koyanagi-Harada (VKH) disease presenting as papillitis vs. serous retinal detachment (SRD). Retrospective comparative cohort study of 35 patients with previously unknown VKH diagnosis, followed-up for ≥6 months. Outcomes measured: (1) time to achieve inflammatory control; (2) VKH relapse; (3) ocular complications (glaucoma, sunset glow fundus, cataract, and vision loss ≥2 Snellen lines); and (4) chances for developing a chronic-recurrent disease. Females predominated in both groups: 12/16 (75%) papillitis and 18/19 (94.7%) SRD. The mean age at presentation was 29 ± 12 years in the papillitis and 36 ± 14 years in the SRD group (p = 0.119), with an overall median follow-up of 26 months (6-180 months). The papillitis-onset VKH group's mean time elapsed between symptoms onset and initial treatment was shorter (2.9 ± 1.0 vs. 4.6 ± 2.8 weeks, p = 0.024). Anterior segment inflammation was lower (56% vs. 79%, p = 0.018), requiring a shorter corticosteroids treatment duration (12.8 ± 16.1 vs. 32.7 ± 34.1 months, p = 0.040), achieving an earlier inflammatory control (1.9 ± 0.6 vs. 4.1 ± 3.2 months, p <0.001) with fewer ocular complications (13% vs. 74%, p <0.001), including sunset glow fundus (SGF) (0% vs. 63%, p <0.001). Conversely, SRD-onset VKH was a risk factor for developing disease relapse (HR: 4.53; 95% CI: 1.31-15.69, p = 0.017), ocular complications (OR: 19.60, 95% CI: 3.24-118.50, p = 0.001), and chronic-recurrent disease (OR: 20.63; 95% CI: 2.24-189.84, p = 0.008). Mexican-mestizo VKH patients with papillitis-onset VKH disease showed earlier inflammatory control, fewer recurrences, and better visual and ocular complication outcomes.

29 May 2025 in Journal of Ophthalmic Inflammation and Infection
Verified
Journal Article
Open access
PDF file
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
ARAlejandro Rodríguez-García
Alejandro Rodríguez-García
CÁCarlos Álvarez-Guzmán
Carlos Álvarez-Guzmán
Purpose: The purpose of this study was to describe the case of a pediatric patient diagnosed with mucous membrane pemphigoid (MMP) with exclusive ocular involvement presenting at diagnosis with peripheral ulcerative keratitis and provide a review of the literature. Methods: A 12-year-old girl presented with cicatricial conjunctivitis and peripheral ulcerative keratitis (PUK). A conjunctival biopsy and direct immunofluorescence revealed linear deposits of IgG, IgM, and C3 at the basement membrane zone, confirming a diagnosis of ocular MMP. Results: The patient was initially treated with dapsone 25 mg/day and prednisone 40 mg/day along with topical treatment including cyclosporine 0.05%, loteprednol etabonate 0.05%, and sodium hyaluronate 0.15% and trehalose 3%. Inflammation persisted as an increase in the extension of symblepharon was documented. Subsequently, dapsone was switched to oral methotrexate 15 mg/week and prednisone was successfully tapered to 5 mg/day. After three years of follow-up, disease activity remained quiescent. Conclusions: Pediatric mucous membrane pemphigoid with ocular involvement is a rare condition of which few reports have been published, resulting in scarce information regarding its clinical course and response to treatment. We report the first case observed in a Hispanic patient, opening with peripheral ulcerative keratitis, and responding successfully to methotrexate.